Inclusion Criteria : 
  1.  age older than 60 years;
  2.  moderate to severe or severe mitral regurgitation;
  3.  symptoms ( New York Heart Association [ NYHA ] cardiac function class â‰¥ 2 ) related to MR;
  4.  the primary regurgitant jet originated from malcoaptation of the A2 and P2 scallops of the mitral valve;
  5.  high risk for surgery according the MVARC criteria;
  6.  providing signed informed consent. 
Exclusion Criteria : 
  1.  acute myocardial infarction in the prior 4 weeks of the intended treatment;
  2.  any interventional or surgical cardiac procedure performed within 30 days prior;
  3.  the need for any other cardiac surgery;
  4.  echocardiographic evidence of intracardiac mass , thrombus , or vegetation;
  5.  life expectancy within 12 months;
  6.  moderate or severe aortic stenosis or regurgitation;
  7.  mitral valve orifice area < 3.5 cm2;
  8.  untreated significant coronary stenosis;
  9.  history of mitral valvuloplasty;
 10.  Infective endocarditis and rheumatic heart disease;
 11.  untreated cardiogenic shock , acute pulmonary congestion;
 12.  unfavored mitral valve anatomy that may preclude device implantation including : 
     calcification or significant cleft in area of the A2 and / or P2 scallops , significant regurgitation beyond A2 or P2 scallops and short posterior leaflet (  < 10 mm ) . 
 13.  Other clinical trials that the subjects participated in have not reached the end point.